A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
In a recent interview, Arjun Sahgal, M.D., discussed current and emerging research examining the potential of MRI-guided adaptive radiotherapy for treating glioblastomas.
While traditional non-adaptive radiotherapy for glioblastomas has reportedly yielded an approximate 11 percent rate of marginal failure, recently presented findings from the UNITED trial revealed that magnetic resonance imaging (MRI)-guided radiation reduced the marginal failure rate to 4.1 percent.
Utilizing the MR-Linac system (Elekta) to facilitate a 5 mm target margin, daily MRI monitoring and weekly changes to a personalized radiotherapy dose plan, the study authors found that 80 percent of patients had a reduction in gross tumor volume (GTV) during treatment.
In a recent interview, Arjun Sahgal, M.D., said the use of the MR-Linac system to facilitate ongoing improvements in targeting with adaptative radiotherapy is a significant advance in the treatment of high-grade gliomas.
“ … You’re constantly evolving to create a personalized radiotherapy field for that patient. … If (the tumor) is getting smaller, you can actually reduce the amount of healthy brain tissue that you radiate. So it’s a whole new paradigm in the approach to glioblastoma that came about as a result of MR-Linac technology,” explained Dr. Sahgal, the chief of radiation oncology at Sunnybrook Odette Cancer Center in Toronto, Canada.
Dr. Sahgal noted that physicians historically obtained MRIs at baseline and three months after radiotherapy treatment for glioblastoma. However, they found in the UNITED trial that over 50 percent of patients with glioblastomas had greater than 5 mm of tumor displacement, on average, during treatment.
“This idea of changing or adapting on a weekly basis to a tumor and adjusting that margin that we take in a personalized way is actually very unique in radiotherapy overall. It has not yet been done in many sites. In fact, we're probably one of the more advanced sites to use the power of adaptive radiotherapy in a clinical trial to date,” noted Dr. Sahgal, the president of the International Stereotactic Radiosurgery Society.
(Editor’s note: For related content, see “What MRI Research Reveals About Tumor Sphericity in Patients with IDH-Wildtype Glioblastoma,” “What Does the Future Hold for Brain Imaging and Radiotherapy?” and “Can AI Help Differentiate Between Tumor Recurrence and Pseudoprogression on MRI in Patients with Glioblastoma?”)
For more insights from Dr. Sahgal, watch the video below.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
